MA pharma gift ban: down but not out

A measure to repeal Massachusetts' pharma gift ban failed to make it into a final economic stimulus bill but may yet resurface.

The amendment to completely strike the ban, attached to the house version of the economic development bill, passed in the final weeks of the legislative session but was dropped due to a shortage of senate votes.

A compromise allowing industry to fund doctors' meals at restaurants, and not just hotels and convention centers, also fell one senate vote short.

The issue, however, could resurface in the upcoming session, where healthcare issues are on the agenda. The fear that the ban could cause medical societies to pull their meetings out of Boston is not going away.

So far, only one society has—the American Academy of Allergy, Asthma & Immunology (AAAAI) canceled a 2015 meeting.

“What we don't know is how many groups have decided to take Massachusetts off the rotation cycle,” said Beth Stehley, VP of sales and convention services for the greater Boston Convention and Visitors Bureau.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.